ES2092296T3 - Metodo de tratamiento de tejidos infectados. - Google Patents

Metodo de tratamiento de tejidos infectados.

Info

Publication number
ES2092296T3
ES2092296T3 ES93908585T ES93908585T ES2092296T3 ES 2092296 T3 ES2092296 T3 ES 2092296T3 ES 93908585 T ES93908585 T ES 93908585T ES 93908585 T ES93908585 T ES 93908585T ES 2092296 T3 ES2092296 T3 ES 2092296T3
Authority
ES
Spain
Prior art keywords
liposomes
entrapped
infected region
vesicle
liposomal composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908585T
Other languages
English (en)
Inventor
Martin C Woodle
Irma A J M Bakker-Woudenberg
Francis J Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Sequus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequus Pharmaceuticals Inc filed Critical Sequus Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2092296T3 publication Critical patent/ES2092296T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN METODO PARA EL TRATAMIENTO DE UN PUNTO DE INFECCION SISTEMATICA QUE CONSISTE EN ADMINISTRAR UN COMPUESTO TERAPEUTICO ATRAPADO EN LIPOSOMAS. TAMBIEN SE PRESENTA UNA COMPOSICION LIPOSOMAL Y UN METODO PARA LA PREPARACION DE LA COMPOSICION LIPOSOMAL A UTILIZAR PARA CONCENTRAR UN COMPUESTO TERAPEUTICO EN UNA REGION INFECTADA A TRAVES DEL FLUJO SANGUINEO. LOS LIPOSOMAS, QUE CONTIENEN EL AGENTE DE FORMA ATRAPADA, SE COMPONEN DE LIPIDOS FORMADORES DE VESICULAS, UN LIPIDO FORMADOR DE VESICULAS DERIVADO CON UN POLIMERO HIDROFILICO BIOCOMPATIBLE, Y SUS TAMAÑOS SE SELECCIONAN DE UNA GAMA DE TAMAÑOS DE ENTRE 0,07 Y 0,2 MICRAS. TRAS LA ADMINISTRACION PARENTERAL, LA REGION INFECTADA TOMA DE FORMA SELECTIVA LOS LIPOSOMAS EN UN PERIODO DE TIEMPO DE 24 A 48 HORAS, PARA LIBERAR EL COMPUESTO ATRAPADO EN LA REGION INFECTADA.
ES93908585T 1992-03-27 1993-03-24 Metodo de tratamiento de tejidos infectados. Expired - Lifetime ES2092296T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/858,171 US5843473A (en) 1989-10-20 1992-03-27 Method of treatment of infected tissues

Publications (1)

Publication Number Publication Date
ES2092296T3 true ES2092296T3 (es) 1996-11-16

Family

ID=25327664

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908585T Expired - Lifetime ES2092296T3 (es) 1992-03-27 1993-03-24 Metodo de tratamiento de tejidos infectados.

Country Status (7)

Country Link
US (1) US5843473A (es)
EP (1) EP0632719B1 (es)
AT (1) ATE142483T1 (es)
DE (1) DE69304685T2 (es)
DK (1) DK0632719T3 (es)
ES (1) ES2092296T3 (es)
WO (1) WO1993019738A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6645463B1 (en) 1994-05-16 2003-11-11 The Board Of Regents Of The University Of Michigan Blood-pool selective carrier for lipophilic imaging agents
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
AU714043B2 (en) * 1994-10-03 1999-12-16 Infectio Recherche Inc. Liposome-formulations for treatment of viral diseases
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US6673364B1 (en) 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
US20110230857A1 (en) * 1997-01-27 2011-09-22 Ewa Herbst Electronic delivery systems and methods with feedback
US20060089751A1 (en) * 1997-01-27 2006-04-27 Ewa Herbst Electronic delivery systems and methods with feedback
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
JP2001524957A (ja) * 1997-04-11 2001-12-04 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン 親油性画像診断剤用の血液プール運搬体
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
WO1999059547A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
WO1999065461A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Cationic amphiphile micellar complexes
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
US20030147944A1 (en) * 1999-12-10 2003-08-07 Mayer Lawrence D Lipid carrier compositions with protected surface reactive functions
WO2001085131A2 (en) * 2000-05-11 2001-11-15 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
AU2002312410A1 (en) * 2001-06-08 2002-12-23 Target Protein Technologies, Inc. Tissue-specific endothelial membrane proteins
JP2005525992A (ja) * 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
JP4555569B2 (ja) * 2001-11-13 2010-10-06 セレーター ファーマシューティカルズ， インコーポレイテッド 増強された血中安定性を有する脂質キャリア組成物
US20030190320A1 (en) * 2002-02-21 2003-10-09 Pietro Speziale Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins
JP2005525375A (ja) * 2002-03-05 2005-08-25 トランセイブ， インク． 生物活性物質をリポソーム又は脂質複合体内に封入する方法
AR036316A1 (es) * 2002-08-29 2004-08-25 Monte Verde S A Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion
ES2439727T3 (es) * 2002-10-29 2014-01-24 Insmed Incorporated Liberación sostenida de antiinfectantes
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
AU2005292083A1 (en) * 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
US20070105757A1 (en) * 2005-10-31 2007-05-10 May Thomas B Vancomycin formulations having reduced amount of histamine
CA2838111C (en) 2005-12-08 2016-01-19 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
WO2007127803A2 (en) * 2006-04-25 2007-11-08 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
JP5333970B2 (ja) * 2007-03-20 2013-11-06 国立大学法人大阪大学 心筋梗塞の予防および／または治療薬
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
AU2008256644B2 (en) 2007-05-24 2014-07-03 The United States Government As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
WO2011160110A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
CN108743537B (zh) 2012-05-21 2021-06-11 英斯麦德公司 治疗肺部感染的系统
US20140023696A1 (en) * 2012-07-20 2014-01-23 Frederick Timothy Guilford Treatment for idiopathic pulmonary fibrosis
CN104884047A (zh) 2012-11-29 2015-09-02 英斯梅德股份有限公司 稳定的万古霉素制剂
US20140234397A1 (en) * 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
WO2014160337A1 (en) * 2013-03-13 2014-10-02 Mallinckrodt Llc Liposomal cisplatin compositions for cancer therapy
MX2016014921A (es) 2014-05-15 2017-07-28 Insmed In Incorporated Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
US20170281541A1 (en) * 2014-09-05 2017-10-05 The Johns Hopkins University Liposome-based mucus-penetrating particles for mucosal delivery
NZ733010A (en) 2014-12-31 2023-01-27 Lantheus Medical Imaging Inc Lipid-encapsulated gas microsphere compositions and related methods
IL262647B2 (en) 2016-05-04 2023-03-01 Lantheus Medical Imaging Inc Methods and devices for preparing sharpness factors for ultrasound
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
EP3500312B1 (en) * 2016-08-18 2024-04-10 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
EP3731846A4 (en) * 2017-12-29 2022-03-02 Wayne State University DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTIONS
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
JPS6376862A (ja) * 1986-09-17 1988-04-07 Nippon Denso Co Ltd 表面硬化層を有するアルミニウム部材
EP0295248B2 (en) * 1986-12-23 1999-04-28 The Liposome Company, Inc. Liposome preparation and antibiotic
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP2666345B2 (ja) * 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
JPH04234841A (ja) * 1988-07-08 1992-08-24 Mitsubishi Rayon Co Ltd 光学活性化合物及び液晶組成物
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5079234A (en) * 1989-03-23 1992-01-07 Bristol-Myers Squibb Co. Inhibitors of aminoglycoside nephrotoxicity
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time

Also Published As

Publication number Publication date
EP0632719A1 (en) 1995-01-11
DK0632719T3 (da) 1997-09-15
DE69304685D1 (de) 1996-10-17
EP0632719B1 (en) 1996-09-11
US5843473A (en) 1998-12-01
ATE142483T1 (de) 1996-09-15
WO1993019738A1 (en) 1993-10-14
DE69304685T2 (de) 1997-04-03

Similar Documents

Publication Publication Date Title
ES2092296T3 (es) Metodo de tratamiento de tejidos infectados.
ATE152614T1 (de) Mittel zur behandlung entzündeter gewebe
NO1999003I1 (no) Pegylert liposomalt doxorubicin
CA2075624C (en) Ultrasound-enhanced delivery of materials through the skin
US20030072814A1 (en) Topical pharmaceutical composition for the treatment of warts
ES2136618T3 (es) Cicatrizacion de heridas.
CA2233961A1 (en) Stimulation of hair follicles
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
CA2251966A1 (en) Transdermally administered dextromethorphan as antitussive agent
EP1063981B1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
CA2064039A1 (en) Treatment to reduce edema for brain and musculature injuries
CA2340898A1 (en) Compositions and methods for treating intracellular infections
RU94036344A (ru) Способ лечения спида
RU93048862A (ru) Способ профилактики и лечения эндометритов у коров "вазокамэтром"

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 632719

Country of ref document: ES